Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

ClinicalTrials.gov ID: NCT00202982

Public ClinicalTrials.gov record NCT00202982. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients

Study identification

NCT ID
NCT00202982
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
90 participants

Conditions and interventions

Interventions

  • glatiramer acetate 20 mg Drug
  • glatiramer acetate 40 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2003
Primary completion
Aug 31, 2005
Completion
Aug 31, 2005
Last update posted
Jan 13, 2010

2003 – 2005

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Center for Neurologic Study La Jolla California 92037
North County Neurology Associates Oceanside California 92056
The MS Center of Atlanta Atlanta Georgia
Consultants in Neurology, Ltd Northbrook Illinois 60062
Indiana University School of Medicine Indianapolis Indiana 46202
The Maryland Center for M.S. Baltimore Maryland
Michigan Institute of Neurological Disorders Farmington Hills Michigan 48334
The Minneapolis Clinic of Neurology, LTD Golden Valley Minnesota 55422
University of Minnesota Minneapolis Minnesota 55455
St. John's Mercy Medical Center St Louis Missouri 63141
Clinical & Magnetic Resonance Research Ctr. Albuquerque New Mexico 87131
MSSM - Corinne Goldsmith Dickinson Center for MS New York New York 10029
University of Rochester Rochester New York 14642
Cleveland Clinic Foundation Cleveland Ohio 44195
Geisinger Medical Center Danville Pennsylvania 17822
Allegheny Neurological Associates Pittsburgh Pennsylvania 15212
University of Tennessee Memphis Tennessee 38163
VAMC Salt Lake City Utah 84148
MS Hub Medical Group Seattle Washington 98101
Neurology & Neurosurgery Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00202982, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 13, 2010 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00202982 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →